摘要
AIM:To analyze the pathogenetic role and potential clinical usefulness of the epidermal growth factor receptor(EGFR)and the human epidermal growth factor receptor 2(HER2)in patients with advanced biliary tract cancer(BTC). METHODS:EGFR and HER2 expression was studied in biopsy samples from 124 patients(51%women; median age 64.8 years),with advanced BTC diagnosed between 1997 and 2004.Five micrometers sections of paraffin embedded tissue were examined by standard, FDA approved immunohistochemistry.Tumors with scores of 2+or 3+for HER2 expression on immunochemistry were additionally tested for HER2 gene amplification by fluorescence in situ hybridisation(FISH).RESULTS:34/124 patients(27.4%)had gallbladder cancer,47(37.9%)had intrahepatic BTC and 43(34.7%)had extrahepatic or perihilar BTC.EGFR expression was examined in a subset of 56 samples. EGFR expression was absent in 22/56 tumors(39.3%). Of the remaining samples expression was scored as 1+in 12(21.5%),2+in 13(23.2%)and 3+in 9(16%), respectively.HER2 expression was as follows:score 0 73/124(58.8%),score 1+27/124(21.8%),score 2+ 21/124(17%)and score 3+4/124(3.2%).HER2 gene amplification was present in 6/124,resulting in an overall amplification rate of 5%. CONCLUSION:Our data suggest that routine testing and therapeutic targeting of HER2 does not seem to be useful in patients with BTC,while targeting EGFR may be promising.
AIM： To analyze the pathogenetic role and potential clinical usefulness of the epidermal growth factor receptor （EGFR） and the human epidermal growth factor receptor 2 （HER2） in patients with advanced biliary tract cancer （BTC）. METHODS： EGFR and HER2 expression was studied in biopsy samples from 124 patients （51% women; median age 64.8 years）, with advanced BTC diagnosed between 1997 and 2004. Five micrometers sections of paraffin embedded tissue were examined by standard, FDA approved immunohistochemistry. Tumors with scores of 2＋ or 3＋ for HER2 expression on immunochemistry were additionally tested for HER2 gene amplification by fluorescence in situ hybridisation （FISH）.RESULTS： 34/124 patients （27.4%） had gallbladder cancer, 47 （37.9%） had intrahepatic BTC and 43 （34.7%） had extrahepatic or perihilar BTC. EGFR expression was examined in a subset of 56 samples. EGFR expression was absent in 22/56 tumors （39.3%）. Of the remaining samples expression was scored as 1＋ in 12 （21.5%）, 2＋ in 13 （23.2%） and 3＋ in 9 （16%）, respectively. HER2 expression was as follows： score 0 73/124 （58.8%）, score 1＋ 27/124 （21.8%）, score 2＋ 21/124 （17%） and score 3＋ 4/124 （3.2%）. HER2 gene amplification was present in 6/124, resulting in an overall amplification rate of 5%. CONCLUSION： Our data suggest that routine testing and therapeutic targeting of HER2 does not seem to be useful in patients with BTC, while targeting EGFR may be promising.
